Arrowhead Pharmaceuticals (NASDAQ:ARWR) had its "overweight" rating reaffirmed by analysts at Piper Sandler. They now have a $110.00 price target on the stock, up previously from $100.00.
Is Arrowhead Pharmaceuticals Stock a Buy or Sell After the CEO Sold Shares Worth $5.4 Million? [Yahoo! Finance]
Assessing Arrowhead Pharmaceuticals (ARWR) Valuation After REDEMPLO Approvals And New Obesity Trial Data [Yahoo! Finance]
Arrowhead Pharmaceuticals Prices Offerings of Notes, Common Stock, Pre-Funded Warrants [Yahoo! Finance]
Arrowhead Pharmaceuticals Prices Upsized Offerings of Convertible Senior Notes, Common Stock and Pre-Funded Warrants